Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00389870 |
|
Recruitment Status : Unknown
Verified July 2007 by National Cancer Institute (NCI).
Recruitment status was: Recruiting
First Posted : October 19, 2006
Last Update Posted : August 26, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cyclosporine may help irinotecan work better by making tumor cells more sensitive to the drug. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Panitumumab may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether irinotecan is more effective when given with or without panitumumab or cyclosporine in treating colorectal cancer.
PURPOSE: This randomized phase III trial is studying irinotecan to compare how well it works when given with or without panitumumab or cyclosporine in treating patients with advanced or metastatic colorectal cancer that did not respond to fluorouracil.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Colorectal Cancer | Biological: panitumumab Drug: cyclosporine Drug: irinotecan hydrochloride | Phase 3 |
OBJECTIVES:
Primary
- Compare the efficacy and toxicity of single-agent irinotecan hydrochloride (Ir) vs Ir with cyclosporine (IrC) in patients with fluorouracil-resistant advanced colorectal cancer.
- Compare the efficacy of single-agent Ir vs Ir with panitumumab (IrP) in these patients.
Secondary
- Correlate the toxicity of Ir and/or IrC with genetic variability in the enzymes involved in irinotecan hydrochloride's disposition pathway.
- Compare IrC to Ir and its metabolites (SN38; SN38G), in terms of pharmacokinetic profile.
- Correlate the benefit of IrP with tumor expression of epidermal growth factor receptor (EGFR) or its known down-stream molecules as a predictive measure.
- Correlate IrP efficacy or toxicity (specifically the severity of skin rash) with somatic alterations in the EGFR gene and/or with germline variability in related genes.
OUTLINE: This is a randomized, open-label, controlled, multicenter study. Patients are stratified according to prior cetuximab (yes vs no). Patients are randomized to 1 of 3 treatment arms.
- Arm I: Patients receive irinotecan hydrochloride IV over 30-90 minutes on day 1.
- Arm II: Patients receive irinotecan hydrochloride IV over 15-40 minutes on day 1 and oral cyclosporine three times a day on days 1-3.
- Arm III: Patients receive panitumumab IV over 30-90 minutes followed by irinotecan hydrochloride IV over 30-90 minutes on day 1. Single-agent panitumumab may be continued during breaks in chemotherapy treatment.
In all arms, treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue treatment in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline and at 12 and 24 weeks.
After completion of study treatment, patients are followed every 12 weeks for 1 year.
Peer Reviewed and Funded or Endorsed by Cancer Research UK
PROJECTED ACCRUAL: A total of 1,269 patients will be accrued for this study.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 1269 participants |
| Allocation: | Randomized |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomised Clinical Trial of Treatment for Fluorouracil-Resistant Advanced Colorectal Cancer Comparing Standard Single-Agent Irinotecan Versus Irinotecan Plus Panitumumab and Versus Irinotecan Plus Ciclosporin [Panitumumab, Irinotecan & Ciclosporin in COLOrectal Cancer Therapy (PICCOLO)] |
| Study Start Date : | December 2006 |
| Estimated Primary Completion Date : | March 2010 |
- Proportion of patients treated with irinotecan hydrochloride (Ir) alone vs Ir and cyclosporine (IrC) who are progression-free at 12 weeks
- Overall survival of patients treated with Ir vs Ir and panitumumab (IrP) and no prior cetuximab
- Proportion of patients free from treatment failure at 12 weeks in patients treated with Ir vs IrC
- Overall survival in patients treated with Ir vs IrC
- Nurse-assessed toxicity (all-cause mortality, diarrhea ≥ grade 3 at 12 weeks) in patients treated with Ir vs IrC
- Progression-free at 12 weeks in patients treated with Ir vs IrP and no prior cetuximab
- Nurse assessed toxicity (all-cause mortality) in patients treated with Ir vs IrP and no prior cetuximab
- Progression-free survival in patients treated with Ir vs IrP and prior cetuximab
- Best response at 1 year in patients treated with Ir vs IrP and prior cetuximab
- Patient-assessed symptom/quality of life/acceptability scores at 12 and 24 weeks in patients treated with Ir vs IrP and prior cetuximab
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
-
Diagnosis of colorectal adenocarcinoma meeting 1 of the following criteria:
- Previous or current histologically confirmed primary adenocarcinoma of the colon or rectum and clinical/radiological evidence of advanced or metastatic disease
- Histologically or cytologically confirmed metastatic adenocarcinoma with clinical or radiological evidence of colorectal primary tumor
- Unidimensionally measurable disease
-
Disease progression during or after prior fluorouracil with or without oxaliplatin therapy and/or with or without bevacizumab
- Adjuvant therapy and/or prior therapy for advanced disease allowed
- No clinical or radiological evidence of pleural effusion or ascites causing ≥ grade 2 dyspnea
- No clinical or radiological evidence of biliary obstruction
- No known CNS metastases or carcinomatous meningitis
PATIENT CHARACTERISTICS:
- WHO performance status 0-2
- Life expectancy ≥ 12 weeks
- Hemoglobin > 10.0 g/dL
- WBC > 3,000/mm³
- Platelet count > 100,000/mm³
- Glomerular filtration rate > 50 mL/min OR EDTA clearance > 60 mL/min
- Bilirubin < 1.46 mg/dL
- Alkaline phosphatase ≤ 5 times upper limit of normal (ULN)
- AST and ALT ≤ 2.5 times ULN
- No history of Gilbert's syndrome
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 6 months after completion of study treatment
- Capable of completing quality of life questionnaires
- No prior anaphylactic allergic reaction to cetuximab
- No other prior or concurrent cancer (excluding nonmelanomatous skin cancer)
- No unresolved bowel obstruction, uncontrolled gastrointestinal infection, chronic enteropathy (e.g., Crohn's disease or ulcerative colitis), or chronic diarrhea (≥ 4 stools per day) of any cause
- No recent history of seizures
- No clinical or radiological evidence of interstitial pneumonitis or pulmonary fibrosis,
- Capable of reliable oral self-medication
- No other condition that would make the patient unsuitable for participation in this study
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No major thoracic or abdominal surgery within the past 4 weeks
- No systemic anticancer therapy within the past 3 weeks
- No prior irinotecan hydrochloride
- No grapefruit juice within 3 days before and after each chemotherapy treatment
- No experimental drug therapy or antibody therapy, other than cetuximab, within the past 6 weeks
- No systemic chemotherapy and/or cetuximab within the past 3 weeks
- No antifungals or antibiotics within the past 5 days
-
No ongoing requirement for cyclosporine or any other medication including, but not limited to, the following:
- Ketoconazole, fluconazole, itraconazole
- Erythromycin, clarithromycin, norfloxacin
- Diltiazem hydrochloride, verapamil, amiodarone hydrochloride
- Fluvoxamine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00389870
Show 33 study locations
| Study Chair: | Matthew T. Seymour, MA, MD, FRCP | Cookridge Hospital |
| ClinicalTrials.gov Identifier: | NCT00389870 |
| Other Study ID Numbers: |
CDR0000510284 CTRU-PICCOLO-MO-05-7289 EUDRACT-2005-003492-20 CTAAC-CTRU-PICCOLO-MO-05-7289 AMGEN-CTRU-PICCOLO-MO-05-7289 EU-20647 |
| First Posted: | October 19, 2006 Key Record Dates |
| Last Update Posted: | August 26, 2013 |
| Last Verified: | July 2007 |
|
recurrent colon cancer stage IV colon cancer recurrent rectal cancer |
stage IV rectal cancer adenocarcinoma of the colon adenocarcinoma of the rectum |
|
Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Cyclosporine Irinotecan Panitumumab Cyclosporins |
Topoisomerase I Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antifungal Agents Anti-Infective Agents Dermatologic Agents Antirheumatic Agents Calcineurin Inhibitors Antineoplastic Agents, Immunological |